Department of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Diabetes Care. 2011 Mar;34(3):730-3. doi: 10.2337/dc10-2083. Epub 2011 Feb 2.
To determine changes in gene expression in epicardial adipose tissue (EAT) associated with coronary atherosclerosis (CAD) and effects of pioglitazone therapy.
Genes were quantified by RT-PCR in EAT and thoracic subcutaneous adipose tissue (SAT) obtained during surgery in CAD patients with metabolic syndrome (MS) or type 2 diabetes and control subjects with minimal or no CAD and no MS or type 2 diabetes.
Increased expression of interleukin-1 receptor antagonist (IL-1Ra) and IL-10, a trend for higher IL-1β, and no change in peroxisome proliferator-activated receptor-γ (PPARγ) was found in EAT from MS or type 2 diabetes. Only PPARγ mRNA was reduced in SAT. Pioglitazone therapy in type 2 diabetes was associated with decreased expression of IL-1β, IL-1Ra, and IL-10 in EAT; decreased IL-10 in SAT; and increased PPARγ in SAT.
In MS and type 2 diabetes with CAD, proinflammatory and anti-inflammatory genes were differentially increased in EAT and selectively reduced in association with pioglitazone treatment.
确定与冠状动脉粥样硬化（CAD）相关的心脏外膜脂肪组织（EAT）中基因表达的变化，以及吡格列酮治疗的影响。
在患有代谢综合征（MS）或 2 型糖尿病的 CAD 患者以及有最小或无 CAD 且无 MS 或 2 型糖尿病的对照者手术期间获得 EAT 和胸皮下脂肪组织（SAT），通过 RT-PCR 定量基因表达。
在 MS 或 2 型糖尿病患者的 EAT 中发现白细胞介素-1 受体拮抗剂（IL-1Ra）和 IL-10 表达增加，IL-1β 呈上升趋势，过氧化物酶体增殖物激活受体-γ（PPARγ）无变化；而 SAT 中仅 PPARγ mRNA 减少。2 型糖尿病患者的吡格列酮治疗与 EAT 中 IL-1β、IL-1Ra 和 IL-10 表达降低，SAT 中 IL-10 降低以及 SAT 中 PPARγ 增加有关。
在患有 CAD 的 MS 和 2 型糖尿病中，EAT 中促炎和抗炎基因表达不同，与吡格列酮治疗相关的基因表达选择性降低。
